LLY Stock Overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Eli Lilly and Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$767.76 |
| 52 Week High | US$972.53 |
| 52 Week Low | US$567.42 |
| Beta | 0.40 |
| 1 Month Change | 1.90% |
| 3 Month Change | -16.68% |
| 1 Year Change | 34.60% |
| 3 Year Change | 181.13% |
| 5 Year Change | 483.76% |
| Change since IPO | 27,236.10% |
Recent News & Updates
Eli Lilly: A Rare Buying Opportunity
Dec 17Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50
Dec 14
Recent updates
Eli Lilly: A Rare Buying Opportunity
Dec 17Eli Lilly (NYSE:LLY) Has Announced That It Will Be Increasing Its Dividend To $1.50
Dec 14Lilly's Head-To-Head Data Lands Blow On Novo In Battle For Weight Loss Supremacy
Dec 04Here's Why Eli Lilly (NYSE:LLY) Can Manage Its Debt Responsibly
Nov 29Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)
Nov 28Eli Lilly Stock: Unexpected Developments (Rating Downgrade)
Nov 21Eli Lilly and Company Just Missed EPS By 31%: Here's What Analysts Think Will Happen Next
Nov 01Taking A Look At Eli Lilly's Q3 2024 Revenue Miss Amid Supply Chain Challenges
Oct 30Eli Lilly Buy On Weakness Signal (Technical Analysis)
Oct 20Eli Lilly: Ebglyss To Challenge Dupixent In Atopic Dermatitis
Sep 30Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Sep 20Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Sep 18Eli Lilly: Zepbound Price Cuts Have Multiple Positives, Limited Downside
Sep 04Eli Lilly: Tirzepatide's Winning Streak Continues
Aug 20Shareholder Returns
| LLY | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.7% | -1.6% | -2.4% |
| 1Y | 34.6% | 7.8% | 23.3% |
Return vs Industry: LLY exceeded the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: LLY exceeded the US Market which returned 23.3% over the past year.
Price Volatility
| LLY volatility | |
|---|---|
| LLY Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: LLY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LLY's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1876 | 43,000 | Dave Ricks | www.lilly.com |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio.
Eli Lilly and Company Fundamentals Summary
| LLY fundamental statistics | |
|---|---|
| Market cap | US$682.11b |
| Earnings (TTM) | US$8.37b |
| Revenue (TTM) | US$40.86b |
82.6x
P/E Ratio16.9x
P/S RatioIs LLY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LLY income statement (TTM) | |
|---|---|
| Revenue | US$40.86b |
| Cost of Revenue | US$7.80b |
| Gross Profit | US$33.06b |
| Other Expenses | US$24.69b |
| Earnings | US$8.37b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 9.30 |
| Gross Margin | 80.91% |
| Net Profit Margin | 20.48% |
| Debt/Equity Ratio | 218.1% |
How did LLY perform over the long term?
See historical performance and comparisonDividends
0.8%
Current Dividend Yield54%
Payout RatioDoes LLY pay a reliable dividends?
See LLY dividend history and benchmarks| Eli Lilly dividend dates | |
|---|---|
| Ex Dividend Date | Feb 14 2025 |
| Dividend Pay Date | Mar 10 2025 |
| Days until Ex dividend | 54 days |
| Days until Dividend pay date | 78 days |
Does LLY pay a reliable dividends?
See LLY dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 11:15 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Eli Lilly and Company is covered by 63 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Ishan Majumdar | Baptista Research |
| Alistair Campbell | Berenberg |